Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2026European Heart Journal

Semaglutide mechanisms of action: the missing pieces

View Full Paper
Ask AI
Bookmark
Share

Authors

Subodh Verma
Subodh VermaInterventional / Structural Cardiology
TGTomasz J GuzikJagiellonian University
Francesco Cosentino
Francesco CosentinoPreventive Cardiology

Discussion

Loading...

Member takes

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

HCHelen ColhounProfessor of medicine, University of Edinburgh

“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty. Whether we combine all risk factors together or look at some subsets of the risk factors, no more than half of the reduction in heart disease could be explained by the changes in these risk factors. These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug.”

News Coverage
Subodh VermaSubodh VermaCardiac surgeon, University of Toronto

“By all accounts, the remarkable story of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in cardiovascular medicine has been one of serendipity. Two years ago, in the European Heart Journal, we wrote that the journey of semaglutide was one such story—a drug born to lower glucose that has become the most versatile weapon against cardiometabolic-, kidney-, and obesity-related disease”

News Coverage

Overview

Narrative review reveals unresolved central and peripheral mechanisms of semaglutide in metabolic disease, highlighting key targets for next-generation drug design.

Key Points

  • To review the established pharmacology of semaglutide and evaluate critical knowledge gaps in its central and peripheral mechanisms of action.
  • Narrative synthesis of preclinical models and clinical trial data investigating semaglutide signaling and physiological outcomes.
  • Semaglutide stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and delays gastric emptying via glucagon-like peptide-1 receptor activation.
  • Appetite suppression is mediated primarily by access to hypothalamic and hindbrain circuits, though exact downstream neuronal populations and non-pancreatic peripheral actions remain incompletely defined.

Cite This Study

Verma et al. (2026) studied this question.

synapsesocial.com/papers/6ab6905b68a7ce8912ee884ehttps://doi.org/10.1093/eurheartj/ehag602
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Effect of Semaglutide on Mortality and COVID-19–Related Deaths2024 · 50 citations
  2. 2Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial2026 · 1 citations
  3. 3Mediation analysis of time‐to‐event endpoints accounting for repeatedly measured mediators subject to time‐varying confounding2019 · 72 citations
  4. 4Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits2025 · 83 citations
  5. 5GLP-1 and the cardiovascular system2026 · 8 citations